Tasly Pharmaceutical Group (600535.SH): TDX105 Granules Receive Drug Clinical Trial Approval
Tasly Pharmaceutical Group (600535.SH) announced that recently, the company received the "Drug Clinical Trial Approval Notice" for TDX105 Granules issued by the National Medical Products Administration (hereinafter referred to as the "NMPA").
Tasly Pharmaceutical Group (600535.SH) announced that the company recently received the Drug Clinical Trial Approval Notice for TDX105 Granules issued by the National Medical Products Administration (hereinafter referred to as the "NMPA").
TDX105 Granules is a Class 1.1 traditional Chinese medicine new drug developed based on a clinical experience formula from the Cancer Hospital of the Chinese Academy of Medical Sciences (National Cancer Center). The formulation composition, usage, and dosage of this product are consistent with the clinical application of the experience formula. This clinical experience formula has been used clinically for many years, and clinical observations show that it has a significant alleviating effect on itching, pain, and other skin damage caused by anti-tumor drug-related skin adverse reactions, with good efficacy and safety.
Related Articles
ZCZL Industrial Technology Group (00564) repurchased approximately 544,500 A shares on October 14 for approximately RMB 7.4903 million.
FUFENG GROUP (00546) repurchased 50,000 shares for HK$220,300 on October 14.
CGN NEW ENERGY (01811) repurchased 704,000 shares for HK$1.5034 million on October 14.
ZCZL Industrial Technology Group (00564) repurchased approximately 544,500 A shares on October 14 for approximately RMB 7.4903 million.
FUFENG GROUP (00546) repurchased 50,000 shares for HK$220,300 on October 14.
CGN NEW ENERGY (01811) repurchased 704,000 shares for HK$1.5034 million on October 14.
